Remote monitoring for gout in primary care
Official title: The Self-management App 'MinUrinsyregikt' for Patients With Gout. The ReMonit Gout Feasibility Study in Primary Care
Run by Diakonhjemmet Hospital · NCT07490522 · Data updated 2026-11-12
This project will test a smartphone self-management app to help adults with gout and high urate levels manage their condition alongside GP follow-up.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Diakonhjemmet Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Status | Recruiting |
| Started | April 2026 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | April 30, 2026 |
| Trial ID | NCT07490522 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with a clinical gout diagnosis, serum urate >360 µmol/L, an indication for urate-lowering therapy, access to a smartphone or tablet, and the ability to understand Norwegian are ideal candidates.
✕Probably not a fit
Patients who are pregnant or breastfeeding, have contraindications to urate-lowering therapy, major comorbidities, or who lack a smartphone or Norwegian language ability are unlikely to benefit from this app-based approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-group, decentralized feasibility project in Norway in which 20–50 adults with gout will use the 'MinUrinsyregikt' self-management app for 3 months while receiving usual GP follow-up. Participants will register tophi presence, urate-lowering medication and dose, medication adherence, flares, and monthly serum urate results in the app, which provides reminders and prompts for blood tests and medications. Data will be collected via baseline and 3-month digital questionnaires and through semi-structured interviews with both patients and GPs about their experiences. GPs remain responsible for medical care and will not access app data; the aim is to test feasibility and inform a future randomized controlled trial.
Why it matters
Potential benefit: If successful, the app could improve medication adherence and timely serum urate monitoring, leading to better gout control in primary care.
How similar studies have gone: E-health self-management interventions for chronic diseases have shown adherence benefits in some pilots, but digital interventions specifically for gout are limited and lack large randomized trial evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Patients are eligible to be included in the study only if all the following criteria apply: * Adults ≥18 years of age at screening * Patients with a clinical diagnosis of gout * Serum urate level \>360 µmol/L at inclusion * Indication for urate lowering therapy assessed by medical doctor * Having a smartphone/tablet Patients are excluded from the study if any of the following criteria apply: * Pregnant or breastfeeding * Contraindication for urate lowering therapy * Does not understand Norwegian language * Major co-morbidities (e.g., malignancies, severe chronic kidney disease, severe mental disorders)
Where it's running
-
Diakonhjemmet Hospital
Oslo, Norway Recruiting
Study contacts
- Principal investigator: Fiona Aanesen — Diakonhjemmet Hospital
- Study coordinator: Fiona Aanesen, PhD
- Email: fiona.aanesen@diakonsyk.no
- Phone: +47 22451500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dotinurad in gout patients who can’t tolerate XOI or failed uricase treatment
This trial tests whether dotinurad can lower uric acid levels in adults with gout who can’t use certain standard medicines or have not benefited from uricase.
-
Orienting project on crystal deposits in gout, CPPD, and osteoarthritis
This project will follow adults with gout or CPPD and people with osteoarthritis to see if crystal deposits in joints and blood vessels change over time and relate to treatments or heart problems.
-
Purified Cortrophin® Gel for treating acute gout flares at two dose levels
This study will try two single injections (40 U and 80 U) of Purified Cortrophin® Gel to see which dose better and more quickly reduces pain in adults having an acute gout flare.
-
IV PRX-115 at different dose schedules, with or without methotrexate, versus placebo for adults with gout
This trial will test whether IV PRX-115 given on different schedules, with or without low-dose methotrexate, can lower uric acid and be safe in adults whose gout is not controlled by standard urate-lowering drugs.
-
Dotinurad versus allopurinol for lowering uric acid in gout
This trial tests whether dotinurad lowers blood uric acid more than allopurinol in adults with gout.
-
Metformin for safety and benefit in people with gout
This trial will test whether metformin is safe and helps reduce gout symptoms in people diagnosed with gout.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.